Immune checkpoint inhibitors in melanoma

Adam J. Cooper, Matteo S. Carlino*, Richard F. Kefford

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    3 Citations (Scopus)

    Abstract

    The potential to harness the power of the immune system and effectively treat patients with metastatic melanoma is finally being realized with the advent of immune checkpoint inhibitors. These new therapies herald a new era in the treatment of melanoma with the potential to produce very durable responses and possible cure for a subset of patients, though bring with them challenges including novel toxicities and nonconventional response patterns. This article reviews the currently available immune checkpoint inhibitors, potential biomarkers to predict response and promising investigational approaches including combination therapies.

    Original languageEnglish
    Pages (from-to)267-284
    Number of pages18
    JournalMelanoma Management
    Volume2
    Issue number3
    DOIs
    Publication statusPublished - Aug 2015

    Keywords

    • Anti-CTLA4
    • Anti-PD-1
    • Anti-PD-L1
    • Checkpoint inhibitor
    • Immunotherapy
    • Ipilimumab
    • Melanoma
    • Nivolumab
    • Pembrolizumab

    Fingerprint

    Dive into the research topics of 'Immune checkpoint inhibitors in melanoma'. Together they form a unique fingerprint.

    Cite this